Breaking News

Recipharm Extends Commercial Mfg. to Support RedHill’s Talicia to 2026

Manufacturing takes place at Recipharm's facilities in Strängnäs, Sweden and Pessac, France, as well as in Fontaine-lès-Dijon France.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Recipharm, a global CDMO, has extended the ongoing commercial manufacturing of RedHill Biopharma’s drug, Talicia for the treatment of H. pylori infection, to 2026.   The companies entered a partnership in 2015 to develop and manufacture Talicia (delayed-release capsules, omeprazole magnesium, amoxicillin and rifabutin, 10 mg/250 mg/12.5 mg). The manufacturing takes place at Recipharm’s facilities in Strängnäs, Sweden and Pessac, France, as well as in Fontaine-lès-Dijon France (previously...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters